We describe the long-term outcomes of autologous hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All patients were in continuous CR for X2 years after HCT. Patients were predominantly transplanted in CR1 (78%) and had good or intermediate cytogenetic risk disease (74%). Median follow-up of survivors was 106 (range, 24-192) months. Overall survival at 10 years after HCT was 94% (95% confidence intervals, 89-97%) and 80% (67-91%) for patients receiving HCT in CR1 and CR2, respectively. The cumulative incidence of relapse at 10 years after HCT was 6% (3-10%) and 10% (3-20%) and that of nonrelapse mortality was 5% (2-9%) and 11% (4-21%), respectively. On multivariate analysis, HCT in CR2 (vs CR1), older age at transplantation and poor cytogenetic risk disease were independent predictors of late mortality and adverse disease-free survival. The use of growth factors to promote engraftment after HCT was the only risk factor for relapse. Relative mortality of these 2-year survivors was comparable to that of age-, race-and gender-matched normal population. Patients who receive autologous HCT for AML in CR1 or CR2 and remain in remission for X2 years have very favorable long-term survival. Their mortality rates are similar to that of the general population.
Introduction
After attainment of an initial remission, patients with AML can receive consolidation therapy with either chemotherapy or hematopoietic cell transplantation (HCT) based on various prognostic factors (for example, age, performance status and cytogenetics). In general, patients with favorable prognostic features receive consolidation chemotherapy only, whereas those with high-risk disease and an acceptable risk of treatment-related morbidity and mortality are offered allogeneic HCT. Autologous HCT has also been investigated as a consolidation therapy for AML and can extend survival in a selected subgroup of patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Although its role has not been clearly defined, autologous HCT continues to be used in the management of patients with AML. For instance, 3049 autologous HCT for AML were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 2000-07 (unpublished observation).
Relapse is the most common cause of treatment failure among patients who receive an autologous HCT for AML and predominantly occurs within the first 2 years after transplantation. [2] [3] [4] [5] [6] [7] [8] [9] [10] 13 Long-term survival and risks for late relapse among patients with AML who survive in remission for 2 years after autologous HCT have not been previously described. We conducted a retrospective cohort study to describe the long-term outcomes of patients receiving an autologous HCT for AML who remain in continuous CR for at least 2 years after transplantation. We also conducted analyses to compare their mortality with that of the general population and to identify patient-, disease-and transplantrelated factors that were predictive of late outcomes.
Patients and methods

Data sources
Data for this study were obtained from the CIBMTR, which is a voluntary group of 4500 transplant centers worldwide. Participating centers register basic information on all consecutive transplants to a statistical center at the Medical College of Wisconsin. Detailed demographic and clinical data are collected on a representative sample of registered patients using a weighted randomization scheme. Compliance is monitored by on-site audits. Patients are followed longitudinally, with yearly follow-up. Computerized checks for errors, physician reviews of submitted data and on-site audits of participating centers ensure the quality of data. Observational studies conducted by the CIBMTR during the time period of this study were carried out with a waiver of informed consent and are compliant with Health Insurance Portability and Accountability Act regulations as determined by the Institutional Review Board and the privacy officer of the Medical College of Wisconsin.
Patients
Our study included patients reported to the CIBMTR who had received an autologous HCT for AML in first or second CR between 1990 and 1998 in North America and were in continuous CR for at least 2 years after transplantation.
Patients were selected from the research database if they had received a first transplant for AML in CR1 or CR2 and had achieved or maintained a CR for at least 2 years after transplantation. Patients who died or who had persistent or recurrent malignancy within 2 years of their transplant date were eliminated from the data set. A completeness index of follow-up data was computed for each team with potentially eligible patients. 14 In addition, the proportion of patients with follow-up of o2 years and with no reported events (relapse or death) was calculated. Some transplant teams follow-up recipients of autologous transplantation less diligently in the longer term, particularly beyond 1 year after the procedure. In order to avoid potential bias from teams with incomplete follow-up and, consequently, incomplete ascertainment of events in the late posttransplant period, the final data set included patients from teams in which the number of patients evaluated at 5 years or later was 450% of the patients alive and disease-free at 2 years after HCT. Follow-up information provided by the centers was used for this study.
A total of 958 patients received a first autologous HCT for AML in CR1 or CR2 in the United States and Canada and were reported to the CIBMTR between 1990 and 1998. Among these, 540 patients were excluded for failure to achieve CR after HCT, or for death or relapse or second transplant within the first 2 years after transplantation. An additional 103 patients were excluded from 21 teams who did not meet the follow-up reporting criteria specified above. The final study population consisted of 315 patients from 63 transplant centers (Table 1 ). The median follow-up of survivors was 106 months (range, 24-192 months). The follow-up completeness index from the time of HCT, which is the ratio of total observed person-time and the potential person-time of follow-up in a study, 14 was 97% at 5 years and 80% at 10 years.
End points
Primary study end points were overall survival (OS), disease-free survival (DFS), relapse and nonrelapse mortality (NRM). For analyses of OS, failure was death from any cause; surviving patients were censored at the date of last contact. DFS was survival in CR; disease relapse or progression and death from any cause were considered as events and patients surviving without disease were censored at the date of last contact. Relapse was defined as recurrence of AML with death as a competing risk. NRM was defined as mortality not related to disease recurrence and relapse was the competing risk. The two competing risks, relapse and NRM, make up the DFS event.
Statistical analyses
Univariate probabilities of OS and DFS were calculated by the Kaplan-Meier estimator; the log-rank test was used for univariate comparisons. 15 Probabilities of NRM and relapse were calculated by using cumulative incidence curves to accommodate competing risks. Estimates of s.e. for the survival function were calculated by Greenwood's formula and 95% confidence intervals (CIs) were constructed using log-transformed intervals.
Potential patient-, disease-and treatment-related prognostic factors (Table 2) for OS, DFS, relapse and NRM were evaluated by multivariate analyses using Cox proportional hazards regression. 16 Multivariate models were built using a stepwise forward selection with a significance level of 0.05. In each model, the assumption of proportional hazards was tested for each variable using a time-dependent covariate. 15 First-order interactions of significant covariates were tested.
We calculated estimates of relative mortality as described by Andersen and Vaeth, 17 taking into account the differences among patients with regard to age, gender, race and nationality using population-based standard mortality tables for North America (USA and Canada). Relative mortality with respect to a transplant recipient is the relative risk of dying at a given time after transplantation as compared with a person of similar age and gender in the general population. Mortality rates with 95% CI for relative mortality that included 1.0 were not considered to indicate a significant difference from the rates in a normal population. Plots for relative excess mortality and their pointwise 95% CI were constructed and were based on the kernel smoothed estimates with a band width of 2 years using the Epanechnikov kernel. 18 All P-values are two sided. All analyses were carried out using SAS statistical software (SAS Institute Inc, Cary, NC, USA). Table 1 details the demographic, disease and transplant characteristics of our study cohort. The majority of patients received HCT in CR1 (78%) and had intermediate cytogenetic risk disease (54%). Patients predominantly received a BM graft (72%) and non-TBI-based conditioning regimen (75%). Purged graft was administered to 44% recipients.
Results
Patient, disease and treatment characteristics
Univariate analyses
Univariate probabilities of OS and DFS and cumulative incidences of relapse and NRM are described by disease status at transplantation in Table 3 . OS at 10 years after HCT was 94% (95% CI, 89-97%) and 80% (95% CI, 67-91%) for patients transplanted in CR1 and CR2, respectively ( Figure 1 ). The probability of DFS at 10 years for CR1 and CR2 patients was 88% (95% CI, 83-93%) and 79% (95% CI, 66-90%), whereas the 10-year cumulative incidence of relapse was 6% (95% CI, 3-10%) and 10% (3-20%), and that for NRM was 5% (95% CI, 2-9%) and 11% (4-21%) (Figure 2 ), respectively.
Multivariate analyses
Results of multivariate analyses for OS, DFS, relapse and NRM are detailed in Table 4 . HCT in CR2, older age at transplantation and poor cytogenetic risk disease were independent predictors of higher late mortality. Compared with age o20 years at the time of HCT, patients receiving HCT at older age had higher risks of overall mortality (relative risk for overall mortality 11.43 (95% CI, 1.37-95.61) for age 20-49 years and 32.44 (95% CI, 3.78-278.4) for age X50 years at HCT). Patients with poor-risk cytogenetics had a relative risk of overall mortality of 12.43 (95% CI, 1.91-81.00), whereas patients with intermediate-risk cytogenetics had comparable mortality risks to patients with good-risk cytogenetics. Patients transplanted in CR2 had 3.81 (95% CI, 1.59-9.12) times Median follow-up of survivors (range), months 106 higher relative risks of mortality compared with patients receiving a transplant in CR1. The same factors also predicted adverse DFS (Table 4 ). The only factor predictive of higher relapse was the use of hematopoietic growth factors to promote engraftment after HCT. Karnofsky performance score o90 at transplantation increased the risks of late NRM.
Causes of death and second cancers
In all, 24 deaths were reported for our study cohort; among these, relapse was the most common cause of death (N ¼ 10). Other causes of death included organ failure (N ¼ 4), second cancer (N ¼ 3) and other causes (for example, accidental death, hemorrhage, other cause not specified; N ¼ 5). The cause of death could not be ascertained for two patients. Among the three patients who died of second cancers, specific cancer types included myelodysplastic syndrome (N ¼ 2) and nonsmall cell lung cancer (N ¼ 1).
Six secondary cancers have been reported among 315 patients included in our cohort. These have included myelodysplastic syndrome (N ¼ 3), nonsmall cell lung cancer (N ¼ 1), cutaneous melanoma (N ¼ 1) and papillary carcinoma of the thyroid gland (N ¼ 1).
Relative mortality
The relative mortality of our study cohort was similar to that of the age-, race-and gender-matched general population starting at 4 years after transplantation ( Figure 3 ).
Discussion
Our study indicates very favorable long-term survival for patients with AML in CR1 or CR2 who receive an autologous HCT and survive in remission for X2 years after transplantation. Mortality rates of these 2-year survivors are similar to the general population mortality rates.
In an analysis from the Bone Marrow Transplant Survivor Study, Bhatia et al. 13 have also described long-term mortality after autologous HCT for AML. Their study included 158 patients with AML who had received an autologous HCT and survived for 2 years after transplantation. The overall relative mortality of their cohort was higher than that of the general population with a standardized mortality ratio of 6.4 (95% confidence intervals, 4.1-9.3). However, mortality rates declined with time after HCT and were no different than those of the general population in a subgroup of patients who had survived for more than 10 years after HCT. A more recent study from the Fred Hutchinson Cancer Research Center has also shown that patients receiving autologous HCT for hematological malignancies who survive in remission for at least 5 years have mortality rates that are higher than those of the general population. 19 In contrast, our study shows that patients with AML who receive an autologous HCT in CR1 and CR2 have relative mortality rates similar to those of the general population starting at 4 years after HCT. In comparison with other studies, our analysis only included patients in CR1 and CR2 and the majority of patients included in our cohort had good-or intermediate-risk cytogenetics. Hence, in contrast to other studies in which relapse was the most common cause of late mortality, patients included in our study had a relatively lower probability of late relapse and were able to enjoy survival rates similar to the general population.
Advanced disease stage (CR2 vs CR1), older age at HCT and presence of high-risk cytogenetic abnormalities are known adverse prognostic factors for AML, and it is not surprising that these factors were associated with higher risks of overall mortality and adverse DFS in our patient cohort. A lower Karnofsky performance status score at transplantation, which may be a surrogate for comorbidities and intensity and toxicity of the previous therapy, was associated with increased risks of late NRM.
The use of hematopoietic growth factors to promote engraftment was the only factor associated with increased risks of relapse. This observation is intriguing and has been reported previously among autologous HCT recipients for lymphoma. 20, 21 In a recent retrospective cohort study from the European Group for Blood and Marrow Transplantation, Gorin et al. 22 have also reported a higher incidence of relapse with peripheral blood vs BMT among 2165 AML patients receiving autologous HCT in CR1. The cumulative incidence of relapse was 56, 46 and 39% among early peripheral blood (p80 days of CR1), delayed peripheral blood (480 days from CR1) and BM graft recipients, respectively (Po0.001). These higher risks for relapse with peripheral blood transplantation persisted even after adjusting for other important risk factors in multivariate analyses. The authors postulated that recruitment of tumor cells after mobilization with growth factors with subsequent higher leukemic contamination of the peripheral blood grafts may have accounted for this higher incidence of relapse. The impact of growth factors on outcomes of allogeneic transplantation for leukemia is also controversial, with some studies associating their use with inferior overall and leukemia-free survival, whereas the majority of studies show no impact on outcomes. [23] [24] [25] [26] [27] In our study, the adverse effect of growth factors on relapse could be secondary to patient-selection factors that we could not account for in our analysis. For instance, our cohort consisted of patients who received their transplant in the 1990s, when the use of growth factors in HCT was emerging and patients at higher risk of relapse may have received growth factors preferentially (for example, among patients who had received greater previous therapy to achieve CR and may have been considered to be at higher risk of delayed engraftment). However, this observation may warrant further investigation in future studies.
It is reassuring that the mortality rates of AML patients who receive an autologous HCT and stay in remission for 2 years are similar to those of the general population. However, late effects of transplantation such as second cancers and other organ-specific late complications can take many years to develop, and studies that include an adequate number of very long-term survivors are still needed to realize the complete risks and impact of late mortality after autologous HCT for AML.
Our study has the limitations of a retrospective cohort design. Our results are also not generalizable to all patients who receive an autologous HCT for AML, as our study was restricted to patients who received their transplant in CR1 and CR2. In addition, only 4% of patients had poor-risk cytogenetics. Cytogenetic risk information from diagnosis was missing for 22% of patients; this was comprised primarily of patients from the earliest time period when cytogenetics were not routinely assessed in AML. In addition, the choice of autologous HCT as consolidation therapy over chemotherapy only or allogeneic HCT was determined by physicians at transplant centers. Factors that may have determined the choice of therapy were not available for analysis.
Our study was not designed to determine the general outcomes of autologous HCT for AML, as our cohort was restricted to AML patients in CR1 and CR2 who survived in remission for X2 years after autologous HCT. A large number of patients who received an autologous HCT for AML relapse within the first 2 years after transplantation; in fact, among the 958 patients who received an autologous HCT for AML in CR1 or CR2 and were reported to the CIBMTR during the study period, 56% experienced treatment failure (relapse or death) within the first 2 years. Our specific objective was to determine long-term outcomes in patients who had survived 2 years or more and had presumably overcome the risks of initial relapse.
In conclusion, our study highlights the very favorable long-term survival among AML patients who receive an autologous HCT in CR1 or CR2 and survive in continuous CR for at least 2 years. Their mortality rates are similar to that of the general population.
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